InsidersTradesSigma
Total declarations
Companies
▲ Purchases (10 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
10
Disclosed sells
0
T+90 hit rate
40%
T+90 mean return
+1.6%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Evans Daron, Chairman & CEO. Insider active across 2 companies, notably NEPHROS INC. Aggregated, 16 disclosures have been published. Breakdown: 10 buys · 0 sell. Total volume traded: €474k. Activity tracked since 24 May 2021. The latest transaction was disclosed on 2 July 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Declarations16 total
3,062 shares@ US$4.99Common SharesSEC:0000912282-26-000929:0
10,000 shares@ US$2.895.6% of flowCommon SharesSEC:0000912282-25-000339:0
Ideal exit: 21 Dec 2025 (T+270)
77,000 shares0Common SharesSEC:0000912282-25-000180:0
10,000 shares@ US$4.298.6% of flowCommon SharesSEC:0000912282-24-000908:0
Ideal exit: 14 Sept 2025 (T+270)
9,000 shares@ US$4.608.3% of flowCommon SharesSEC:0000912282-24-000884:0
Ideal exit: 8 Sept 2025 (T+270)
10,549 shares@ US$5.049.6% of flowCommon SharesSEC:0000912282-24-000863:0
Ideal exit: 6 Sept 2025 (T+270)
40,000 shares@ US$4.039231.7% of flowCommon SharesSEC:0000912282-24-000494:0
Ideal exit: 11 Mar 2025 (T+270)
451 shares@ US$3.500.3% of flowCommon SharesSEC:0000912282-24-000472:0
Ideal exit: 23 Feb 2025 (T+270)
58 shares@ US$2.850.0% of flowCommon SharesSEC:0000912282-24-000460:0
Ideal exit: 17 Feb 2025 (T+270)
20,000 shares@ US$1.69156.6% of flowCommon SharesSEC:0000912282-24-000274:0
Ideal exit: 10 Dec 2024 (T+270)
50,000 shares@ US$1.926918.5% of flowCommon SharesSEC:0000912282-24-000232:0
Ideal exit: 3 Dec 2024 (T+270)
41,900 shares@ US$1.298610.6% of flowCommon SharesSEC:0000912282-24-000163:0
Ideal exit: 12 Nov 2024 (T+270)
349 shares@ US$2.7012.0% of flowCommon StockSEC:0000914190-21-000169
349 shares@ US$2.700.0015% mcap12.0% of flowCommon StockSEC:0000914190-21-000169:0
1,111 shares@ US$2.7038.0% of flowCommon StockSEC:0000914190-21-000162
1,111 shares@ US$2.700.0047% mcap38.0% of flowCommon StockSEC:0000914190-21-000162:0
16 of 16 declarations
About Evans Daron
Daron Evans is the CEO of Specialty Renal Products at Nephros Inc. He is responsible for the strategic and operational direction of this division. His expertise is essential in ensuring innovation and growth in the healthcare sector.
